(2019) compared systemic administration with topical biomaterial loading of IL-10, and found that systemic IL-10 treatment attenuated TNFα and IL-1β production at 24 h post-SCI, but failed to reach significance at 7 days post-SCI, which were similar to the results of previous studies.
1
—
—